Trial ID or NCT#





This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.

Official Title

NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: 2 Years to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Sheri L. Spunt, MD, MBA
Pediatric oncologist, Sarcoma specialist
Endowed Professor of Pediatric Cancer
Neyssa Marina

Contact us to find out if this trial is right for you.


Ped Hem/Onc CRAs